Additional Details

  • WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF)

    WISPer site in Kansas City, KS
    Kansas City KS. 66160
    View Details

  • WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF)

    WISPer site in Dallas, TX
    Dallas TX. 75204
    View Details

  • WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF)

    WISPer site in Oklahoma City, OK
    Oklahoma City OK. 73104
    View Details

  • WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF)

    WISPer site in New York, NY
    New York NY. 10032
    View Details

  • WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF)

    WISPer site in Loxahatchee, FL
    Loxahatchee Groves FL. 33470
    View Details

  • WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF)

    WISPer Site in Palm Springs, CA
    Palm Springs CA. 92203
    View Details

  • WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF)

    WISPer site in Greensboro, NC
    Greensboro NC. 27403
    View Details

  • WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF)

    WISPer site in Shreveport, LA
    Shreveport LA. 71103
    View Details

  • WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF)

    WISPer site in Ajax, ON
    Ajax ON. L1S 2J5
    View Details

  • WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF)

    WISPer site in Phoenix, AZ
    Phoenix AZ. 85032
    View Details

  • WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF)

    WISPer site in Champaign, IL
    Champaign IL. 61822
    View Details

  • WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF)

    WISPer site in Newport Beach, CA
    Newport Beach CA. 92663
    View Details

  • An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)

    Columbia University
    New York NY. 10032
    View Details

  • An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)

    CIC Mauricie
    Trois-Rivières QC. G8T 7A1
    View Details

  • An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)

    Centre for Lung Health
    Vancouver V5Z1M9
    View Details

  • An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)

    Medical University of South Carolina
    Charleston SC. 29425
    View Details

  • An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)

    Renstar Medical Research
    Ocala FL. 34470
    View Details

  • An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)

    University of Cincinnati
    Cincinnati OH. 45267
    View Details

  • An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)

    The University of Kansas Medical Center
    Kansas OH. 66160
    View Details

  • An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)

    Southeastern Research Center
    Winston-Salem NC. 27103
    View Details